Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)

Launched by UNIVERSIDADE DO PORTO · Jul 4, 2024

Keywords

ClinConnect Summary

The LOOK-UP study is a research trial that aims to keep an eye on the safety of a medication called Rinvoq™ (upadacitinib), which is used to treat various inflammatory conditions like rheumatoid arthritis and ulcerative colitis. This study is important because it helps gather information about any side effects or safety concerns that may arise after people start using this medicine. They are currently looking for participants who are 18 years or older, have been prescribed Rinvoq™ starting January 1, 2024, and are willing to take part in the study.

If you join the LOOK-UP study, you’ll be asked to answer some questions over the phone to help the researchers understand how Rinvoq™ is affecting you. It’s important to note that if you have any serious cognitive issues that make it hard to answer questions, or if you’re currently involved in another clinical trial, you won't be able to participate. The study is open to everyone, regardless of gender, and aims to include a wide range of participants to ensure comprehensive safety monitoring of this medication.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Prescription of Rinvoq™ from January 1, 2024;
• • 18 years of age or older at the time of recruitment; and
• • Expressed consent to participate in the study.
• Exclusion Criteria:
• • They have any degree of cognitive impairment that prevents them from responding to a questionnaire administered by telephone;
• • They are participating in a phase I, II, or III clinical trial;
• • They have a life expectancy of less than 1 month; or
• • They do not have a valid telephone contact.